Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Comment by MeanGreenon Oct 06, 2021 11:30am
95 Views
Post# 33973530

RE:The duty of Loyalty for a CEO

RE:The duty of Loyalty for a CEO

I'm can't argue with any of this except to say that they are finally bringing products to market. they should be launching more Cannabinoid products for the consumer markets soon. They are hoping to increase revenues in the short to medium term. 

They say the reason for having multiple approaches to biosynthesis is for cost effectiveness. If they need a Pharma grade product they can use integrasyn, if they need food grade they can use yeast etc.  

there is an excellent team joining from baymedica which should help. 


I agreee I'm not pleased with it either, but there are some good things happening. 

<< Previous
Bullboard Posts
Next >>